Reclassification of marijuana opens doors for much‑needed medical research into the benefits and risks of the drug

When the U.S. Department of Justice moved to reclassify medical marijuana to a Schedule III drug on April 23, 2026, it set the stage for a vast amount of medical research that has been hobbled for decades by its more restrictive Schedule I classification.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup